New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
09:09 EDTEW, MDTMedtronic reports court to expedite appeal in Edwards Lifesciences case
Medtronic (MDT) issued an updated statement on the recent ruling by Federal District Court of Delaware. The ruling granted in part Edwards Lifesciences' (EW) motion for a preliminary injunction that prevents Medtronic from selling or offering to sell its CoreValve System in the U.S., except through a mechanism that Medtronic is pursuing with Edwards Lifesciences that would allow currently trained sites to treat patients with CoreValve based on a physician's medical judgment. The injunction will go into effect on April 23. Medtronic has asked the U.S. Circuit Court of Appeals to postpone the injunction until it can determine if the injunction was properly issued. The Court has not yet ruled. Medtronic also requested, and the Court agreed to, an expedited appeal of the injunction ruling, and other underlying legal issues, with the last appeal brief to be submitted by June 19. Medtronic does not believe Edwards Lifesciences, which brought the motion for a preliminary injunction, has met the standards needed for an injunction, particularly with respect to the impact it will have on the public health interest. As written in the District Court order, Medtronic and Edwards Lifesciences have entered into discussions in an effort to agree on a mechanism that will enable physicians at facilities currently trained on CoreValve 'to make clinical, patient-by-patient determinations as to whether to implant without being constrained by the number of CoreValve...available.' On May 21, Medtronic and Edwards are to report the status of these discussions to the District Court, but if an agreement is reached before that time, it may be implemented.
News For MDT;EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
11:03 EDTMDTMedtronic expects Emerging Markets to grow in mid-teens
Expects Emerging Markets to grow in mid-teens, adding 150-200 bps to overall annual revenue growth. Expects EM exposure of approximately 13% of comparable, constant currency revenue mix in FY15. Comments taken from slides for Bernstein Annual Strategic Decisions Conference.
May 27, 2015
10:01 EDTMDTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abbott (ABT) initiated with a Buy at Evercore ISI... Aldeyra (ALDX) initiated with a Buy at Janney Capital... Black Stone Minerals (BSM) initiated with a Neutral at Credit Suisse... Boston Scientific (BSX) initiated with a Buy at Evercore ISI... Cidara Therapeutics (CDTX) initiated with a Buy at BTIG... Coach (COH) initiated with an Underweight at BB&T... Diplomat Pharmacy (DPLO) initiated with an Outperform at Raymond James... EPIRUS (EPRS) initiated with a Buy at BTIG... Enviva (EVA) initiated with a Buy at Citigroup... General Finance Corp (GFN) initiated with an Outperform at Oppenheimer... Hortonworks (HDP) initiated with an Outperform at Oppenheimer... Jarden (JAH) initiated with a Buy at UBS... Kate Spade (KATE) initiated with a Buy at BB&T... Medtronic (MDT) initiated with a Hold at Evercore ISI... MoneyGram (MGI) initiated with a Neutral at Goldman... Opexa Therapeutics (OPXA) initiated with a Buy at Maxim... Paratek Pharmaceuticals (PRTK) initiated with a Buy at BTIG... Progenics (PGNX) initiated with a Buy at BTIG... Rite Aid (RAD) initiated with a Buy at Mizuho... St. Jude Medical (STJ) initiated with a Buy at Evercore ISI... Starwood Waypoint (SWAY) initiated with an Outperform at Wells Fargo... Talen Energy (TLN) initiated with a Hold at Deutsche Bank... Ulta Salon (ULTA) initiated with a Buy at Buckingham... Vipshop (VIPS) initiated with a Buy at Stifel... Virtu Financial (VIRT) initiated with a Neutral at Citigroup... Vista Outdoor (VSTO) initiated with a Buy at Wunderlich... ZELTIQ (ZLTQ) initiated with a Buy at Northcoast... eBay (EBAY) initiated with a Buy at Topeka.
06:05 EDTMDTAcacia subsidiary signs settlement agreement with Covidien LP
Acacia Research's (ACTG) Advanced Skeletal Innovations and Bonutti Skeletal Innovations subsidiaries have entered into a settlement agreement with Covidien (COV) LP f/k/a Tyco Healthcare Group, a subsidiary of Medtronic (MDT). The agreement resolves litigation that was pending in the U.S. District Court for the District of Columbia.
May 26, 2015
17:45 EDTMDTMedtronic initiated with a Hold at Evercore ISI
Subscribe for More Information
09:54 EDTMDTMedtronic looking for deals in China, WSJ reports
Subscribe for More Information
May 21, 2015
20:04 EDTMDTMedtronic CEO sees untapped potential in India, Times of India says
Subscribe for More Information
May 20, 2015
09:34 EDTMDTMedtronic announces new data for drug-coated balloon
Subscribe for More Information
07:16 EDTMDTLeerink to hold a booth tour at EuroPCR
Subscribe for More Information
05:30 EDTEWEdwards Lifesciences announces outcomes for patients treated with SAPIEN 3 valve
Edwards Lifesciences announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve at centers in Europe and Canada demonstrated very low mortality and stroke rates, and no severe paravalvular leaks. These independently adjudicated data are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States. In the multi-center study of 101 intermediate-risk patients, all-cause mortality was 1 percent. The frequency of other important complications was also low: the disabling stroke rate was 2 percent, major vascular complications were 2 percent and the permanent pacemaker rate was 4 percent. The investigators also noted that the SAPIEN 3 valve had excellent hemodynamic performance, with very low incidence of significant paravalvular regurgitation, as only 2.3 percent of patients had moderate paravalvular leaks and there were no reports of severe leaks.
May 19, 2015
09:21 EDTEWEdwards Lifesciences voluntarily pauses enrollment for Fortis clinical program
Subscribe for More Information
08:48 EDTEWEdwards Lifesciences reports positive results from treatment with SAPIEN 3
Subscribe for More Information
08:40 EDTMDTMedtronic sees FY15 revenue $20.3B, may not compare to consensus $28.15B
Subscribe for More Information
08:40 EDTMDTMedtronic sees Q4 adjusted EPS at upper half of $1.08-1.13, consensus $1.10
Subscribe for More Information
May 18, 2015
09:27 EDTMDTMedtronic announces study results showing CRT system optimizes treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use